UCB SA (OTCMKTS:UCBJF) Short Interest Update

UCB SA (OTCMKTS:UCBJF) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 403,500 shares, a decrease of 17.0% from the October 15th total of 486,100 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 4,035.0 days.

UCB Trading Down 10.1 %

Shares of OTCMKTS:UCBJF traded down $19.76 during trading on Friday, reaching $175.00. The stock had a trading volume of 183 shares, compared to its average volume of 317. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $181.79 and a two-hundred day simple moving average of $157.75. UCB has a 52 week low of $72.25 and a 52 week high of $194.76.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.